| Literature DB >> 34903208 |
Hossein Esmaeilzadeh1,2,3, Negar Mortazavi4, Alireza Salehi5,6, Hossein Fatemian7, Seyed Mohsen Dehghani8, Mohebat Vali9, Hossein Molavi Vardanjani5.
Abstract
BACKGROUND: Kawasaki Disease (KD) is the most common childhood vasculitis and cause of acquired heart disease for no apparent reason. There is some evidence indicating infectious agents as possible triggers for KD. During the COVID-19 pandemic, vasculitis has been a presentation of COVID-19 in children. We performed this study to assess the association between KD and COVID-19. We evaluated KD hospitalized children during February to September 2020 for COVID-19 (group one) and compared their demographic, clinical, laboratory, and echocardiographic findings with KD patients from the same period time in 2019 (group two). We also compared the same data in COVID-19 positive and COVID-19 negative KD patients in 2020 pandemic period in Shiraz Namazi referral hospital at southwest of Iran.Entities:
Keywords: Age; COVID-19; Kawasaki; Pandemic; Skin
Mesh:
Year: 2021 PMID: 34903208 PMCID: PMC8666466 DOI: 10.1186/s12887-021-03060-w
Source DB: PubMed Journal: BMC Pediatr ISSN: 1471-2431 Impact factor: 2.125
Demographics, clinical, and laboratory findings (group 1 vs group 2)
| Age | 5.03 | 4.38 | 5.50 | 0.044 | 29 |
| Male% | 60% (n = 46) | 65% (n = 21) | 56% (n = 25) | 0.438 | 8 |
| Hospital course (days) | 4.47 | 5.13 | 4.00 | 0.555 | 30 |
| Conjunctivitis | 38 (50%) | 14 (43.8%) | 24 (52.2%) | 0.353 | 7 |
| Lymphadenopathy | 27 (36%) | 9 (28.1%) | 18 (39.1%) | 0.250 | 11 |
| Oral mucosa or lips changes | 44 (58%) | 16 (50%) | 28 (60%) | 0.160 | 9.1 |
| Rash | 47 (62%) | 19 (59%) | 28 (60.1%) | 0.706 | 3.5 |
| Extremity changes | 44 (58%) | 19 (59%) | 25 (54.3%) | 0.824 | 3.7 |
| Abnormal echocardiography findings (regarding coronary arteries) | 33 (43%) | 11 (34%) | 12 (26%) | 0.534 | 7.4 |
| ESR(mm/h) | 62.01 | 75.79 | 57.5 | 0.068 | 46.1 |
| CRP (mg/L) | 55.00 | 50.39 | 58.25 | 0.707 | 10 |
Group one sub groups in COVID-19 pandemic: Demographic, clinical, and laboratory findings (COVID-19 positive vs COVID-19 negative)
| Age | 4.38 | 4.32 | 4.50 | 0.967 |
| Male% | 65% (n = 21) | 72% (n = 16) | 50% (n = 5) | 0.725 |
| Hospital course (days) | 5.13 | 5.77 | 3.70 | 0.212 |
| Conjunctivitis | 14 (44%) | 10 (45.5%) | 4 (40%) | 0.773 |
| Lymphadenopathy | 9 (28%) | 7 (31.8%) | 2 (20%) | 0.491 |
| Oral mucosa or lips changes | 16 (50%) | 11 (50%) | 5 (50%) | 0.315 |
| Rash | 19 (59%) | 16 (72%) | 3 (30%) | 0.023 |
| Extremity changes | 19 (59%) | 13 (59%) | 6 (60%) | 0.961 |
| Abnormal echocardiography findings (regarding coronary arteries) | 11 (34%) | 7 (31.8%) | 4 (40%) | 0.04 |
| ESR(mm/h) | 75.79 | 71.05 | 86.23 | 0.398 |
| CRP (mg/L) | 50.39 | 53.86 | 43.10 | 0.269 |
| Elevated D-Dimer | - | 5 (22.7%) | - | - |
| Elevated Ferritin | - | 3 (13.6%) | - | - |
| Elevated LDH | - | 3 (13.6%) | - | - |
| Elevated Fibrinogen | - | 2 (9.09%) | - | - |
| Elevated Procalcitonin | - | 2 (9.09%) | - | - |
| Decreased ALBumin | - | 6 (27.2%) | - | - |
Group one sub groups in COVID-19 pandemic vs Group two: laboratory findings (adjusted to age)
| 19(43.18)% | 10(45.45)% | 3(30.00%) | 0.862 | 0.448 | |
| 16(36.36%) | 7(31.81%) | 4(40.00%) | 0.716 | 0.831 | |
| 10(22.72%) | 7(31.81%) | 4(40.0%) | 0.429 | 0.264 | |
| 18(40.90%) | 8(36.36%) | 5(50.0%) | 0.724 | 0.602 | |